MedTrace Logo

Spinal Cord Stimulation in Spinal Muscular Atrophy

NCT05430113 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-03-16

Study results available
· View outcomes & findings →

Summary

Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with type 3 or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 3 or 4 SMA aged 16 or older that show quantifiable motor deficits of the legs but are able to stand independently. The investigators will then implant the subjects with percutaneous, bilateral, linear spinal leads near the lumbar spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.

Conditions

  • Spinal Muscular Atrophy Type 3
  • Spinal Muscular Atrophy Type 4

Interventions

DEVICE

Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)

2-4 leads FDA-approved for treatment of symptoms of refractory pain

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Marco Capogrosso

    lead OTHER

Principal Investigators

  • Marco Capogrosso · University of Pittsburgh

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2024-01-22
Completion
2025-01-13
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05430113 on ClinicalTrials.gov